28.97
-0.30 (-1.02%)
-0.30 (-1.02%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Halozyme Therapeutics Incorporated | HALO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Previous Close | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.30 | -1.02% | 28.97 | 28.61 | 29.48 | 29.19 | 29.27 | 20:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 27.00 | 32.25 | 5.25 | 16.28% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 8,120 | 745,592 | $ 29.05 | $ 21,661,441 | 1,192,473 | 12.71 - 29.87 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:45:09 | priorref | 14,805 | $ 28.97 | USD |
Halozyme Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 3.93B | 135.81M | 120.78M | $ 195.99M | $ -102.52M | -0.50 | -38.38 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Halozyme Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HALO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 27.51 | 29.6354 | 26.67 | 28.49 | 921,275 | 1.46 | 5.31% |
| 1 Month | 28.02 | 29.87 | 26.25 | 28.04 | 933,780 | 0.95 | 3.39% |
| 3 Months | 23.67 | 29.87 | 22.11 | 25.72 | 1,242,069 | 5.30 | 22.39% |
| 6 Months | 19.73 | 29.87 | 12.71 | 21.91 | 1,502,504 | 9.24 | 46.83% |
| 1 Year | 16.71 | 29.87 | 12.71 | 20.05 | 1,395,455 | 12.26 | 73.37% |
| 3 Years | 13.05 | 29.87 | 11.41 | 18.49 | 1,089,443 | 15.92 | 121.99% |
| 5 Years | 22.1466 | 29.87 | 6.96 | 15.58 | 1,215,149 | 6.82 | 30.81% |
Halozyme Therapeutics Description
| Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
